First Aid Shot Therapy rakes in $24 mln Series C

By Iris Dorbian — 3 months ago

Burlingame, California-based First Aid Shot Therapy, a developer of over-the-counter medicine in liquid shot form, has raised $24 million in Series C funding. Johnson & Johnson Innovation – JJDC Inc led the round with participation from other investors that included Lumira Capital, Sofinnova Ventures, Redmile Group and HealthQuest Capital.

Continue

Gritstone Oncology racks up $102 mln Series A

By Iris Dorbian — 4 months ago

San Francisco Bay area-based Gritstone Oncology, a cancer immunotherapy company, has raised $102 million in Series A financing. The investors included Versant Ventures, The Column Group, Clarus Ventures, Frazier Healthcare Partners, Redmile Group, Casdin Capital and Transformational Healthcare Opportunity.

Continue

VC-backed Ovid Therapeutics names business development VP

By Iris Dorbian — 4 months ago

New York-based Ovid Therapeutics Inc, a biopharmaceutical company focused on treating rare and orphan brain diseases, has hired Dr. Anna Kazanchyan as senior vice president of business development. Previously, Dr. Kazanchyan was the founder and managing partner of Primary i-Research LLC. Ovid’s backers included Fidelity Management and Research Company, Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates (on behalf of certain clients), Redmile Group and Cormorant Asset Management.

Continue

VC-backed CytomX Therapeutics files for IPO

By Iris Dorbian — 5 months ago

South San Francisco-based CytomX Therapeutics, a biopharmaceutical company focused on treating cancer, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be determined. The company plans on trading the stock on the NASDAQ under the ticker symbol “CTMX.” BofA Merrill Lynch, Jefferies LLC and Cowen and Company LLC will serve as the lead underwriters. CytomX’s backers include Fidelity Management & Research Company, Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners and Wellington Management Company.

Continue

Genetic medicine company WAVE Life Sciences nets $66 mln

By Iris Dorbian — 6 months ago

Boston-based genetic medicine company WAVE Life Sciences has closed $66 million in Series B funding. Foresite Capital led the round with participation from other investors that included Fidelity Management and Research Company, New Leaf Venture Partners, Redmile Group, Jennison Associates (on behalf of certain clients), Cormorant Asset Management and RA Capital Management. Leerink Partners served as the placement agent.

Continue

Ovid Therapeutics racks up $75 mln Series B

By Iris Dorbian — 6 months ago

New York-based Ovid Therapeutics Inc, a biopharmaceutical company focused on treating rare and orphan brain diseases, has closed a total of $75 million in Series B funding. Fidelity Management and Research Company led the round with participation from other investors that included Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Redmile Group, Cormorant Asset Management and DoubleLine Equity Healthcare Fund LLC. Cowen and Company was the placement agent.

Continue

Afferent Pharmaceuticals racks up $55 mln Series C

By Iris Dorbian — 7 months ago

San Mateo, California-based Afferent Pharmaceuticals, a developer of drugs that treat neurogenic respiratory, urologic and pain disorders, has closed $55 million in Series C funding. Fidelity Management & Research Company led the round with participation from other investors that included Jennison Associates LLC (on behalf of certain clients), New Leaf Ventures, Partner Fund Management, Redmile Group, Tekla Healthcare Investors and Tekla Life Science Investors.

Continue

Scanadu scores $35 mln Series B

By Iris Dorbian — 10 months ago

Silicon Valley-based medical tech company Scanadu Inc has raised $35 million in Series B funding. Fosun International and Tencent Holdings Limited led the round with participation from China Broadband Capital, Iglobe Partners, Relay Ventures, Redmile Group, Ame Cloud Ventures and Three Leaf Ventures. In conjunction with the funding, Dr. Robert Harrington and Ezra Kucharz have been added to Scanadu’s board of directors.

Continue

Jounce Therapeutics picks up $56 mln Series B

By Iris Dorbian — 10 months ago

Cambridge, Massachusetts-based Jounce Therapeutics, which is focused on discovering and developing cancer immunotherapies, has closed $56 million in Series B funding. The investors included Wellington Management Company, Redmile Group, Nextech Invest, Pharmstandard International, S.A., Cormorant Asset Management, Omega Funds, Casdin Capital and Foresite Capital Management.

Continue

Redmile Group leads Series B round for Scioderm

By Iris Dorbian — 1 year ago

Scioderm, a Durham, NC-based pharmaceutical firm, has closed $20 million in Series B funding. Redmile Group led the round with participation from other investors that included Morganthaler Ventures and Technology Partners. J.P. Morgan Securities was the placement agent on the transaction.

Continue

Blueprint Medicines ropes in $50 mln

By Iris Dorbian — 1 year ago

Blueprint Medicines has raised $50 million in Series C funding. Partner Fund Management led the round with participation from other investors that included Wellington Management Company, RA Capital, Tavistock Life Sciences, Perceptive Advisors, Sabby Capital, Cowen Investments, Redmile Group, Fidelity Biosciences and Third Rock Ventures. Based in Cambridge, Mass., Blueprint Medicines is a developer of kinase inhibitors for genomically defined cancers.

Continue

One Medical raises a healthy $40 mln in growth funding

By Alastair Goldfisher — 2 years ago

One Medical Group, a San Francisco-based provider of healthcare services, has raised $40 million in growth capital in a round led by Redmile Group. Current investors also participated in the round. One Medical previously raised $76.5 million in funding from Benchmark Capital, DAG Ventures, Oak Investment Partners, Google Ventures and Maverick Capital.

Continue

Health diagnostics ‘tricorder’ maker Scanadu raises $10.5 mln from Relay Ventures, Tony Hsieh, Jerry Yang

By Alastair Goldfisher — 2 years ago

Scanadu, a developer of personalized health electronics, has raised $10.5 million in Series A funding that was led by Relay Ventures. Other investors include Tony Hsieh’s VegasTechFund, Jerry Yang’s Ame Cloud Venture, Broe Group, Mindful Investors and Redmile Group. Scanadu previously raised $1.7 million in a crowdfunding campaign on the Indiegogo platform that was launched in May. The company has now raised $14.7 million in funding to date. Scanadu, which is based at the NASA Ames Research Center in Moffett Field, Calif., makes a medical sensor device inspired by the tricorder on “Star Trek” to diagnose information about a patient, such as cardiovascular health. Scanadu founder and CEO Walter De Brouwer told peHUB that the company expects to begin shipping in March.

Continue

Castlight Appoints Driscoll as President

By Angela Sormani — 4 years ago

Castlight Health, a provider of health care transparency solutions for employers and payers, has appointed John Driscoll as president. Castlight Health is headquartered in San Francisco and backed by investors including Allen & Company, Cleveland Clinic, Maverick Capital, Morgan Stanley Investment Management, Oak Investment Partners, Redmile Group, T. Rowe Price, U.S. Venture Partners, Venrock, Wellcome […]

Continue

Oxford Nanopore Closes on $41M

5 years ago

Oxford Nanopore Technologies Ltd., a UK-based developers of nanopore technology, has sealed 25 million pounds ($41 million) in new funding. Lansdowne Partners, IP Group, Invesco Perpetual, Redmile Group, Illumina and other undisclosed investors participated in the round. The company had previously raised 49 million pounds. Oxford Nanopore was formed in 2005, and will use the money for continued development.

Continue